| Code | CSB-RA015215MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar of MAb-AR20.5 (BrevaRex®), targeting MUC1 (CD227)—a high-molecular-weight type I transmembrane mucin glycoprotein with a large extracellular VNTR (tandem repeat) domain. In many epithelial cancers, MUC1 is overexpressed and aberrantly glycosylated (hypoglycosylated), which increases exposure of tumor-associated epitopes and supports malignant phenotypes such as enhanced survival and metastatic progression, making MUC1 a long-standing tumor antigen in oncology research.
MAb-AR20.5 is a murine anti-MUC1 monoclonal antibody raised against the tandem-repeat protein backbone of tumor-associated MUC1 and recognizes a minimal DTRPAP motif within the VNTR region; binding can be influenced by MUC1 glycosylation status, which is central to distinguishing tumor-associated from normal MUC1. This biosimilar provides the antibody component alone, enabling researchers to investigate MUC1 epitope exposure and glycoform-dependent binding, cell-surface engagement, and immune-complex / uptake mechanisms relevant to MUC1-directed immunobiology, without confounding effects from additional therapeutic payloads or formulation variables.
There are currently no reviews for this product.